Figure 5.

Antiviral activity of site 1 −1 PRF binders against SARS-CoV-2. A) Table of analogs with increased potency against B.1.1.7 SARS-CoV-2 than geneticin. EC₅₀: half-maximal effective concentration, CC₅₀: half-maximal cytotoxic concentration. B,C,D) Mechanism of action of AB-3285. B) Vero-E6 were infected with SARS-CoV-2 at MOI 0.1 for 1 hour at 37°C. After the removal of the inoculum, AB-3285 (250 μM) was added to the well. At 0, 4, 8 and 24 hours post.-infection cells were lysed and viral RNA was quantified. C) Dual luciferase evaluation was performed at 24 hours post-transfection in Vero-E6 cells treated with AB-3285 (500 μM). The frameshift efficiency was normalized compared to untreated. D) Binding pose of AB-3285 in the PRF binding site 1. The results are mean and SEM of at least two independent experiments performed in duplicate. P values <0.0332 (*), <0.0021 (**), <0.0002 (***), < 0.0001 (****)